Infectious Disease · Medical Literature
[Correspondence] Rapid recruitment for a remote long COVID clinical trial
Abstract
There have been few long COVID clinical trials relative to the burden of disease,1 and even fewer have been accessible to people with more severe illness.2 As a person who has had moderate-to-severe long COVID (depending on the day) since 2020, I have long advocated for at-home access to clinical trials.3–5
Clinical relevance
Can a fully decentralized, remote-enrollment clinical trial design successfully and rapidly recruit participants with long COVID — including those who are housebound or bedbound — into a rigorous placebo-controlled intervention study? __SNAPSHOT__ {"studyDesign":"Correspondence/Commentary (published in The Lancet Infectious Diseases); describes the design and rapid recruitment experience of LoCITT-T (Long COVID Treatment Trial–Tirzepatide), a decentralized Phase 2 double-blind, randomized, placebo-controlled trial. No original efficacy or safety data are reported in this correspondence.","setting":"Fully remote/decentralized trial platform (CareEvolution MyDataHelps app); Scripps Research Translational Institute, La Jolla, CA, USA. Participants enrolled from across the United States.","sampleSize":"Target enrollment: n=1,000 (intervention: ~500 tirzepatide, control: ~500 placebo). ClinicalTrials.gov lists actual enrollment as 1,000 (NCT07128082). Recruitment reportedly closed by December 2025.","population":"Adults ≥18 years residing in the US with documented long COVID meeting the NASEM definition (infection-associated chronic condition present for ≥3 months after SARS-CoV-2 infection); required internet-connected device and ability to read English or Spanish; excluded if currently using tirzepatide or a similar GIP/GLP-1 agent or if pre-existing ME/CFS preceded COVID-19 infection. Approximately one-quarter of long COVID patients are estimated to be housebound — a population historically excluded from site-based trials.","intervention":"Tirzepatide (dual GIP/GLP-1 receptor agonist, FDA-approved for type 2 diabetes, obesity, and obstructive sleep apnea), administered via self-injection at home following video call guidance from study nurses, using the approved dosage schedule with titration monitoring. Study drug supplied by Eli Lilly and Company.","comparator":"Placebo injection, administered identically at home; double-blind design.","primaryOutcome":"Not fully specified in the abstract/correspondence. Per supplementary trial documentation, the primary endpoint is a validated patient-reported outcome measure (PROM) of symptom burden; wrist-worn wearable (Garmin) data are being collected as exploratory endpoints for future primary endpoint validation. Specific PROM instrument and pre-specified threshold not reported in the Lancet correspondence.","followUp":"12 months of medication/placebo administration and survey completion; primary completion estimated December 2026.","fundingSource":"Non-profit/philanthropic: Schmidt Initiative for Long Covid (SILC). Study drug provided by Eli Lilly and Company (industry). Operated by Scripps Research in partnership with CareEvolution."}
Key findings
This is a correspondence piece reporting the design rationale and rapid recruitment success of LoCITT-T, not a results paper. No efficacy data, primary outcome results, p-values, confidence intervals, effect sizes, or adverse event rates are reported. The key finding of the correspondence is operational: the fully decentralized trial design enabled enrollment of the full target of 1,000 participants — reportedly achieved rapidly, with eligibility verification closed by December 2025, approximately 6 weeks after the trial launched in October 2025. This recruitment speed and the inclusion of housebound and bedbound participants (estimated at >25% of long COVID patients, based on the team's prior Long COVID Wearable Study in which participants walked a median of 2,872 steps/day) are presented as evidence of concept for decentralized trial feasibility in this population. No NNT, NNH, or comparative statistics are calculable from this correspondence. Efficacy and safety results are anticipated approximately 14 months after completion of recruitment.
Practice implications
This correspondence establishes that decentralized, fully remote clinical trial infrastructure can achieve rapid, large-scale enrollment in long COVID — a condition where a substantial minority of patients (estimated >25%) are housebound or bedbound and therefore categorically excluded from traditional site-based trials. The author, who discloses lived experience with moderate-to-severe long COVID, advocates that this model addresses a documented equity gap in trial access. What the correspondence does NOT establish: (1) whether tirzepatide is effective or safe for long COVID — no efficacy data are presented; (2) whether remote enrollment produces a representative or generalizable sample relative to the broader long COVID population; (3) whether the primary PROM endpoint will be adequately sensitive to detect clinically meaningful change, particularly given the known confounding effect of post-exertional malaise on symptom self-report. Patients not represented include those without internet access, those unable to self-administer injections, those outside the US, non-English/non-Spanish speakers, individuals with pre-existing ME/CFS prior to COVID-19, and current users of GIP/GLP-1 agents. Clinicians should not interpret this correspondence as evidence supporting off-label tirzepatide use for long COVID — this is a trial-design communication, not a treatment evidence report. Only abstract/correspondence text was available for review; full publication analysis was not possible. __LIMITATIONS__ 1. This is a correspondence, not a results paper — no efficacy, safety, or patient-reported outcome data are available for clinical interpretation. 2. The primary outcome instrument is not fully specified in the abstract; PROM-based endpoints in long COVID are subject to subjectivity and post-exertional malaise–driven fluctuation, potentially limiting sensitivity. 3. Decentralized enrollment may introduce selection bias toward patients with greater health literacy, internet access, and functional capacity, despite the intent to include severely ill patients. 4. The trial is restricted to US residents, limiting international generalizability. 5. Eli Lilly provides study drug; while funding is philanthropic, industry drug supply in a commercially active product class (GLP-1 agonists) warrants transparency. 6. Subgroup analyses by demographics, comorbidities (ME/CFS overlap, POTS), and illness severity are planned but pre-specified analytical thresholds and multiplicity adjustments are not described in the correspondence. 7. Absence of validated biomarker endpoints means biological mechanism of any effect (or lack of effect) will remain uncertain. 8. The sample size of 1,000 may still be insufficient to detect benefit in biologically defined subgroups if the overall treatment effect is null. __BOTTOM_LINE_CATEGORY__ promising_but_preliminary __BOTTOM_LINE__ This Lancet Infectious Diseases correspondence reports that the LoCITT-T decentralized trial successfully enrolled 1,000 participants with long COVID — including housebound individuals historically excluded from site-based trials — via a fully remote platform within approximately 6 weeks of launch. No treatment efficacy or safety data are reported; tirzepatide's effect on long COVID symptoms remains unknown and under active investigation, with results anticipated in late 2026 or 2027. Clinicians should not use this correspondence to guide prescribing decisions regarding tirzepatide for long COVID.